.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Abstractvortrag
V238

CUSP9v3 verfügt in vitro über eine starke antineoplastische Aktivität gegen das Medulloblastom

The drug repurposing approach CUSP9v3 has a strong antineoplastic activity against medulloblastoma in vitro

Appointment

Date: 27/06/2023

Time: 15:40 – 15:50

Talk time: 7 Min.

Discussion time: 3 Min.

Location / Stream:

C7.3

Session

Neuroonkologie experimentell II

Topic

Neuroonkologie

Authors

Christopher Loehmann (Ulm), Annika Hajosch (Ulm), Richard Eric Kast (Burlington/ US), Michal Hlavac (Ulm), Mike-Andrew Westhoff (Ulm), Markus David Siegelin (New York, NY/ US), Marc-Eric Halatsch (Winterthur/ CH), Christian Rainer Wirtz (Ulm), Georg Karpel-Massler (Ulm)